➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Johnson and Johnson
AstraZeneca
Colorcon
Mallinckrodt

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,154,990

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,154,990 protect, and when does it expire?

Patent 10,154,990 protects OFEV and is included in one NDA.

This patent has forty-nine patent family members in thirty-two countries.

Summary for Patent: 10,154,990
Title:Medicaments for the treatment or prevention of fibrotic diseases
Abstract: The present invention relates to the use of indolinones of general formula ##STR00001## substituted in the 6 position, wherein R.sub.1 to R.sub.5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
Inventor(s): Park; John Edward (Warthausen, DE), Roth; Gerald Juergen (Biberach, DE), Heckel; Armin (Biberach, DE), Chaudhary; Nveed (Southampton, GB), Brandl; Trixi (Allschwil, CH), Dahmann; Georg (Warthausen-Birkenhard, DE), Grauert; Matthias (Biberach an der Riss, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:14/982,179
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 10,154,990

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No   Start Trial   Start Trial USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)   Start Trial
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 RX Yes Yes   Start Trial   Start Trial USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,154,990

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04030770Dec 24, 2004

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Harvard Business School
Colorcon
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.